Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone

Current Medical Research and Opinion

Volumn 25, Issue 4, 2009, Pages 903-910

  Blumenstein, Matthias ^a,f   Romaszko, Jerzy ^b   Calderón, Alberto ^c   Andersen, Karl ^d   Ibram, Ghionul ^e   Liu, Zhaohui ^e   Zhang, Jack ^e  

^a UNIVERSITY OF MUNICH   (Germany)

^b PANTAMED Sp z oo   (Poland)

^c Centro de Salud Rosa Luxemburgo   (Spain)

^d UNIVERSITY OF ICELAND   (Iceland)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Klinik Augustinum Munchen   (Germany)

Author keywords

Aliskiren; Direct renin inhibitor; Hydrochlorothiazide; Hypertension; Non responder; Single pill combination

Indexed keywords

ALISKIREN PLUS HYDROCHLOROTHIAZIDE; CREATININE; HYDROCHLOROTHIAZIDE; UREA;

ADULT; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN ALLERGY; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; VERTIGO;

ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 66149089653     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902804158     Document Type: Article

References (18)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252 (Pubitemid 37553153)
2. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187 (Pubitemid 46924065)
3. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003;1:43-50
4. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-1018 (Pubitemid 40354519)
5. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006;29:997-1005 (Pubitemid 46206586)
6. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-1163 (Pubitemid 46400330)
7. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-226 (Pubitemid 44885684)
8. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-1055 (Pubitemid 351664315)
9. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-599 (Pubitemid 351317270)
10. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719 (Pubitemid 47176510)
11. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br Med J 2004;328:634-640
12. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-259 (Pubitemid 38293331)
13. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998;12:861-866 (Pubitemid 29010276)
14. Sica D, Gradman AH, Lederballe O, et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006;27(Suppl):121 P-797
15. Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007;21:780-787 (Pubitemid 47450003)
16. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006;48:219-224 (Pubitemid 44309815)
17. Vaidyanathan S, Jarugula V, Dieterich H-A, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47:515-531 (Pubitemid 351969826)
18. Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264-277 (Pubitemid 47091546)